These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27421766)

  • 1. Transcervical administration of polidocanol foam prevents pregnancy in female baboons.
    Jensen JT; Hanna C; Yao S; Thompson E; Bauer C; Slayden OD
    Contraception; 2016 Nov; 94(5):527-533. PubMed ID: 27421766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of tubal occlusion after transcervical polidocanol foam (PF) infusion in baboons.
    Jensen JT; Hanna C; Yao S; Bauer C; Morgan TK; Slayden OD
    Contraception; 2015 Aug; 92(2):96-102. PubMed ID: 26070857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of tubal patency following transcervical administration of polidocanol foam: initial studies in rhesus macaques.
    Jensen JT; Hanna C; Yao S; Micks E; Edelman A; Holden L; Slayden OD
    Contraception; 2014 Jun; 89(6):540-9. PubMed ID: 24560476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polidocanol induced tubal occlusion in nonhuman primates: immunohistochemical detection of collagen I-V.
    Slayden OD; Lee DO; Yao S; Jensen JT
    Contraception; 2016 Nov; 94(5):521-526. PubMed ID: 27417518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of stability of polidocanol foam for nonsurgical permanent contraception.
    Guo JX; Lucchesi L; Gregory KW
    Contraception; 2015 Aug; 92(2):103-7. PubMed ID: 26070858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.
    Mauck CK; Baker JM; Barr SP; Abercrombie TJ; Archer DF
    Contraception; 1997 Aug; 56(2):89-96. PubMed ID: 9315417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubal patency during the menstrual cycle and during treatment with hormonal contraceptives: a pilot study in women.
    Jensen JT; Patil E; Seguin J; Thurmond A
    Acta Radiol; 2017 Aug; 58(8):1020-1025. PubMed ID: 27856803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcervical polidocanol as a nonsurgical method of female sterilization: a pilot study.
    Jensen JT; Rodriguez MI; Liechtenstein-Zábrák J; Zalanyi S
    Contraception; 2004 Aug; 70(2):111-5. PubMed ID: 15288214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic polidocanol from intravenous or pressurized intrauterine administration produces reversible cardiovascular toxicity.
    Jensen JT; Leung P; Roberts M; Guo J; Yao S; Mishler E; Grenz T; Hodovan J; Slayden OD; Lindner JR
    JVS Vasc Sci; 2022; 3():316-335. PubMed ID: 36439699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine fluid instillation to confirm tubal occlusion after transcervical permanent contraception: A pilot study
    Patil E; Thurmond A; Hart K; Seguin J; Edelman A; Jensen JT
    Contraception; 2020 Jan; 101(1):40-45. PubMed ID: 31655066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
    Sonalkar S; McClusky J; Hou MY; Borgatta L
    Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of repeated transcervical quinacrine pellet insertions for female sterilization.
    el Kady AA; Nagib HS; Kessel E
    Fertil Steril; 1993 Feb; 59(2):301-4. PubMed ID: 8425622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcervical polidocanol as a nonsurgical method of female sterilization: a pilot study.
    Lippes J
    Contraception; 2005 Jan; 71(1):78-9; author reply 79. PubMed ID: 15639079
    [No Abstract]   [Full Text] [Related]  

  • 14. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcervical sterilization with use of methyl 2-cyanoacrylate and a newer delivery system (the FEMCEPT device).
    Shuber J
    Am J Obstet Gynecol; 1989 Apr; 160(4):887-9. PubMed ID: 2712121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.